Aktis Oncology (NASDAQ:AKTS) Sets New 12-Month Low – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $18.80 and last traded at $18.90, with a volume of 181220 shares traded. The stock had previously closed at $19.75.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday.

Aktis Oncology Stock Down 5.0%

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc bought 2,222,222 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the transaction, the director owned 4,348,658 shares in the company, valued at $78,275,844. This represents a 104.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Helen Susan Kim bought 835,000 shares of the business’s stock in a transaction on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This represents a 17.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders purchased 6,117,776 shares of company stock valued at $110,119,968.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.